Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Sells 1,500 Shares Under 10b5-1 Trading Plan

Jazz Pharmaceuticals CEO Bruce Cozadd sold 1,500 ordinary shares at $122.31 per share on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Bruce C Cozadd, Chairman & CEO of Jazz Pharmaceuticals plc, reported a transaction involving the sale of ordinary shares.
• On February 3, 2025, Mr. Cozadd sold 1,500 ordinary shares at a price of $122.31 per share.
• The transaction was executed under a Rule 10b5-1 trading plan.
• Following the transaction, Mr. Cozadd beneficially owns 439,744 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was part of a pre-planned trading arrangement (Rule 10b5-1) and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Sales by insiders are a common occurrence and are often planned in advance, especially when executed under a 10b5-1 trading plan. Investors often monitor insider transactions for signals about a company's prospects, but sales under a pre-arranged plan are generally less informative.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Jazz Pharmaceuticals, Bruce Cozadd, share sale, Form 4, Rule 10b5-1, insider trading, JAZZ